Cipla's animal healthcare product infringes patent: US court

30 Jun 2011 Evaluate

Cipla has received an order from US court, ruling that sales of its animal healthcare product allegedly infringed a patent held by Merial. The sales of the PetArmor Plus have been suspended in the US. The company is in process of filling appeal against the order.

The company’s net profit for the quarter ended March 31, 2011 has declined by 22.33% at Rs 214.00 crore as compared to Rs 275.53 crore for the quarter ended March 31, 2010. Its total income has increased by 19% to Rs 1689.55 crore for the quarter under review from Rs 1419.77 crore in the corresponding previous quarter.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 15:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×